Plan Sponsors Saving on Prescription Drugs Amidst Rising Costs and Inflation

July 22, 2024

Earlier this month, Navitus, a pharmacy benefits manager (PBM), released its eighth annual drug trend report that reveals how plan sponsors are saving on prescription drugs amidst rising costs and inflation. The report shows that 29% of Navitus customers paid less for prescription drugs in 2023 than they did the previous year, despite inflation and the rise of expensive GLP-1 medications

In the report, Navitus shares that their ability to out-perform industry trends in rising drug costs is the result of their, “strategic approach that focused on delivering the lowest net cost to clients, 100% transparency on drug costs and a people-first mission.” 

According to the report, new clients realized an average of 11% reduction in costs compared to the previous year, with a different PBM. 

Prescription drug spending was impacted by a number of industry-wide trends over the past year including rising drug costs and utilization in the non-specialty category, clinical advancements and the introduction of higher-cost specialty drugs and the availability of lower cost alternatives. 

The rise of costly GLP-1s, such as Ozempic and Mounjaro were the biggest contributors to trend growth in 2023. In order to combat these rising costs, Navitus took advantage of a diagnosis check program to help combat off-label use of GLP-1s, mitigating 30% of prescriptions being filled without an appropriate diagnosis. 

Additionally, the launch of biosimilar products for Humira reduced drug spend for clients with utilizing members. Navitus expects that the rising use of injectable biologic drugs will lower costs in 2024 as “utilization shifts drive the industry towards more competitive drug pricing.”

“The rising drug costs and growing demand for GLP-1s were partially offset by lower-cost alternatives including specialty biosimilars and generics,” said Brent Eberle, RPh, Chief Pharmacy Officer at Navitus. “Plans are depending on Navitus to provide transparency to drug cost to help them make informed decisions and weed out needless expenses so they can pass along savings to their employees and members.” 

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

Empowered by Strategic Opportunities and Service Excellence

Empowered by Strategic Opportunities and Service Excellence

Putnam | Northern Westchester Health Benefits Consortium (PNW HBC) was the first municipal cooperative health plan in the state of New York to become certified by the Department of Insurance. They are dedicated to meeting — and exceeding — the standards…

QALYiQ Program Delivers Significant Savings for Both Members and Health Plans

QALYiQ Program Delivers Significant Savings for Both Members and Health Plans

As part of their treatment plan for hypophosphatasia (HPP), a rare genetic disorder affecting bone and teeth development, one of our members required Strensiq, a medication designed to manage HPP. However, Strensiq’s annual treatment costs ranged from…

RISE: Reporting and Intervention for Stars Excellence

RISE: Reporting and Intervention for Stars Excellence

RISE is a comprehensive Star Ratings Improvement program that focuses on positive outcomes for Medicare Part D (Part D) clinical measures, including: medication adherence for diabetes medications, medication adherence for hypertension, medication adherence…

Medication Therapy Management: Improving Health Outcomes and Reducing Cost

Medication Therapy Management: Improving Health Outcomes and Reducing Cost

Patients with chronic diseases can face greater risks for medication-related challenges such as non-adherence. This can lead to poor health outcomes and higher plan costs. That’s why we developed an MTM program, offered through our Clinical Engagement…

previous arrow
next arrow